What we found on the web about Bexxar
It sells in the U.S. under the trade name Bexxar. There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.
It sells in the U.S. under the trade name Bexxar. There is some evidence that it may cause a smaller decrease in platelet counts than ibritumomab tiuxetan does.
Bexxar [package insert]. Seattle, WA: Corixa Corp.; 2003. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated ...
infusions of the BEXXAR therapeutic regimen discontinued and receive medical. 9 ... BEXXAR Therapeutic Regimen. 61 ... BEXXAR Dosimetric Packaging. 68 ...
place a description for your webpage here ... Bexxar treatment - patient release instructions ... Bexxar full prescribing information. A good overview of the ...
Accurate, FDA approved Bexxar information for healthcare professionals and patients - brought to you by Drugs.com. ... The Bexxar therapeutic regimen ...
Listing for Bexxar in FDA Approved Drug Therapies Archives from CenterWatch Clinical Trials Listing Service ... The BEXXAR therapeutic regimen (Tositumomab and ...
Bexxar (tositumomab) is used to treat certain forms of non-Hodgkin lymphoma. ... Bexxar may cause serious allergic reactions, especially in patients who have ...
Bexxar is the trade name for Tositumomab. Tositumomab and Iodine I - 131 is another name for Tositumomab. Bexxar is a monoclonal antibody that is linked with a radioactive atom ...
The Angeles Clinic and Research Institute, Inc. Center for Molecular Medicine 11818 Wilshire Boulevard Suite 200 Los Angeles California 90025 310.231.2140 office 310.231.2141 fax ...
PRESCRIBING INFORMATION BEXXAR ® (Tositumomab and Iodine I 131 Tositumomab) WARNINGS Hypersensitivity Reactions, including Anaphylaxis: Serious hypersensitivity reactions ...
Who is Bexxar for? "BEXXAR is indicated for the treatment of patients with CD20 ... The effects of the BEXXAR therapeutic regimen on survival are not known. ...
More information about Bexxar: Health Minute: Newly approved therapy successfully targets cancer (Jan. 2004) http://www.med.umich.edu/opm/newspage/2004/bexxar.htm
Here is what users have to say about Bexxar

Tositumomab is a monoclonal antibody derived from immortalized mouse cells. It is a IgG2a anti-CD20 antibody and is covalently bound to 131I. 131I emits both beta and gamma radiation and decays with a half-life of 8 days.

Welcome to CWAnswers

CWAnswers is your guide to the sprawling world wide web. The directory aims to provide a useful guide made by users. You can share your knowledge as well - simply register and edit your first entry. For questions just contact the team at support - at - cwanswers.com.

Weblinks

Top 10

Things you find nowhere else.

Comments

You must be logged in to post a comment.

No comments yet on this topic. Be the first one!
These recent articles mention Bexxar
Tribune
The Stanford group studied two immunotherapy agents Bexxar, which is Iodine-131 based and Zevalin, which is Yttrium-90 based. Iodine-131 and Yttrium-90 are radioactive and emit particulate radiation. The immunotherapy agents home in on the ...
Globe and Mail
Ninety-five per cent responded to Bexxar, co-invented by Dr. Kaminski in 1990, with 75 per cent having full remission five years later. While gratified with the results, Dr. Kaminski said more studies are needed to determine if Bexxar could...
Fremont Tribune
In January she was given Bexxar through intravenous injection. Designed as a treatment for lymphoma, it joins an antibody and the radioactive isotope iodine-131. Because of the radioactive substance, Givens said she couldn’t be around her c...
San Jose Business Journal
The Burlingame company said Buckley was most recently vice president of manufacturing at Fremont-based Genitope Corp. Before that he was vice president-Bexxar operations for Corixa Corp. The privately held company focuses on technology plat...
Street.Com
The worry among investors is that Corixa's acquisition could backfire if the FDA fails to clear Bexxar, although Coulter possesses technology that would broaden its appeal and perhaps offset anything that happens to Bexxar, Tanner said. ...
Science Daily
ScienceDaily (June 7, 2007) — Eight years after being treated with a new drug for non-Hodgkin's lymphoma, 86 percent of patients were still alive and half had not had a relapse of their disease, according to researchers from the University ...